Viatris and Teva Pharmaceutical Industries recently launched separate recalls related to dissolution problems for a common anxiety medication and concerns around an unapproved raw material in a high blood pressure patch, respectively.
Viatris, Teva kick off separate recalls over dissolution, raw material issues
Latest from Blog
STAT+: Cell therapy primed liver transplant patients to avoid organ rejection, small study shows
Immune tolerance has long been the holy grail in transplant medicine, a hoped-for end to the downsides of anti-rejection regimens for patients after they receive lifesaving organ transplants. A small, early-stage study
Vetflix Receives 2026 Global Recognition Award for Its Modular Approach to Pet Nutrition and Supplement Adherence
Vetflix has won a 2026 Global Recognition Award in Research and Innovation for its modular, adherence-focused approach to pet nutrition. The com… Post Views: 2
School Meals and Nutrition Education in NYC’s FY27: What’s Funded and What’s Missing
New York City’s Fiscal Year 2027 Preliminary Budget, totaling approximately $127 billion, maintains funding… Post Views: 3
Infusd Nutrition’s emulsion tech enables functional food formats with non-soluble ingredients
Amid ongoing consumer “pill fatigue,” the nutrition industry is exploring new formats to meet demands for fun and convenient formats, such as gummies and functional foods or beverages. However, it is challenging
STAT+: HaloMD’s legal win highlights the difficulty of challenging arbitration decisions
Arbitration decisions, it turns out, are like cockroaches. They’re very hard to kill. It’s a long held truism in the legal world, and it was underscored this week when a federal judge